Peptides for the treatment or prevention of COVID-19

Hexameric TIP peptides, like AP301, provide a safe and effective treatment for severe COVID-19 by reducing severity scores, improving lung function, and lowering mortality risk through inhalation, addressing the lack of effective interventions for severe cases.

JP7579356B2Active Publication Date: 2024-11-07APEPTICO FORSCHUNG & ENTWICKLUNG
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022567567
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-08
Filing Date
2020-09-11
Publication Date
2024-11-07
Estimated Expiration
2040-09-11

AI Technical Summary

Technical Problem

There is an urgent need for safe and effective pharmaceutical interventions for the prevention or treatment of severe COVID-19, particularly for patients with a severity score greater than 4, as existing treatments have not shown efficacy in severe cases.

Method used

The use of hexameric TIP peptides, such as AP301 or Solnatide, which do not exhibit TNF receptor binding activity, administered via inhalation or other routes, to treat or prevent COVID-19, especially in patients at risk or with severe symptoms, combined with other agents if necessary.

Benefits of technology

The peptides effectively reduce severity scores, improve lung compliance, lower body temperature, and decrease the risk of death in COVID-19 patients, as demonstrated by clinical trials and ICU observations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579356000002
    Figure 0007579356000002
  • Figure 0007579356000003
    Figure 0007579356000003
  • Figure 0007579356000004
    Figure 0007579356000004
Patent Text Reader

Abstract

The present invention provides a peptide for use in preventing or treating COVID-19 in patients, the peptide consisting of 7 to 17 amino acids, comprising the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or unnatural amino acid, and exhibiting no TNF receptor binding activity. Solnatide (cyclo-CGQRETPEGAEAKPWYC) is a preferred peptide for use in the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The field of the invention relates to peptides for the prevention or treatment of coronavirus disease 2019 (COVID-19). [Background technology]

[0002] COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). See, for example, Rodriguez-Morales et al., 2020, PubMed unique identifier (PMID) 32179124, Jiang et al., 2020, PMID 32133578, and Tay et al., 2020, PMID 32346093. COVID-19 became a pandemic in 2020.

[0003] The most common symptoms of COVID-19 are fever, dry cough, and fatigue. Other less common symptoms include aches and pains, nasal congestion, headache, conjunctivitis, sore throat, diarrhea, loss of taste and smell, or a skin rash or discoloration of the fingers or toes.

[0004] Importantly, COVID-19 can affect the lungs and cause pneumonia. In severe cases, COVID-19 can rapidly progress to acute respiratory distress syndrome (ARDS), leading to respiratory failure, septic shock, or multiple organ failure. Other complications associated with COVID-19 include sepsis, abnormal clotting, and damage to the heart, kidneys, and liver.

[0005] Several pharmaceutical interventions have been proposed and are currently undergoing clinical trials. These include antivirals such as remdesivir, favipiravir, lopinavir, ritonavir, ribavirin, taribavirin, umefenovir, amantadine, camostat, and TMC-310911; chloroquines such as hydroxychloroquine and chloroquine; anti-interleukin-6 receptor antibodies such as sarilumab and tocilizumab; interferon-beta and angiotensin-converting enzyme 2. On May 1, 2020, the US FDA issued an emergency use authorization for remdesivir for patients hospitalized with severe COVID-19. This is because results from a large clinical trial suggested a shortened recovery time. None of these interventions have been shown to be effective in patients with severe and advanced COVID-19.

[0006] In addition, symptomatic treatments are known: patients severely affected by COVID-19 may receive oxygen therapy, mechanical ventilation, renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO), usually in the setting of an intensive care unit (ICU). According to the World Health Organization (WHO), the severity of the disease can be scored from 0 to 8 as shown in Table 1 below.

[0007] Table 1 - WHO scoring for severity of COVID-19 [Table 1] Summary of the Invention [Problem to be solved by the invention]

[0008] However, there is a dire need for safe and effective pharmaceutical interventions against COVID-19. Accordingly, it is an object of the present invention to provide pharmaceutical prevention or treatment of COVID-19, particularly severe COVID-19 (e.g., severity score >4). [Means for solving the problem]

[0009] The present invention relates to a peptide for use in the prevention or treatment of COVID-19 in a patient, the peptide consisting of 7-17 amino acids, comprising the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or unnatural amino acid, and exhibits no TNF receptor binding activity. Such peptides are referred to herein as TIP peptides.

[0010] The present invention also provides Obtaining a pharma- ceutically acceptable formulation comprising a peptide consisting of 7 to 17 amino acids, comprising the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or unnatural amino acid, and which does not exhibit TNF receptor binding activity; and administering an effective amount of the formulation to a patient having or at risk of developing COVID-19; The present invention provides a method of delaying the onset of COVID-19 or treating COVID-19 comprising administering to a subject a peptide comprising:

[0011] The TIP peptide, AP301 or solnatide (cyclo-CGQRETPEGAEAKPWYC; CGQRETPEGAEAKPWYC is SEQ ID NO:1), has received compassionate use authorization in Austria and Italy for the treatment of COVID-19 patients. Clinical trials are currently ongoing (see Examples section below).

[0012] A TIP peptide is a peptide that contains a human tumor necrosis factor (TNF) lectin-like domain (TIP domain). The TIP domain has been covered, for example, by van der Goot et al., 1999, PMID 10571070. As used herein, a TIP peptide consists of 7-17 amino acids that contain the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or unnatural amino acid, and the peptide does not exhibit TNF-specific inflammatory activity (Hribar et al., 1999, PMID 10540321; Elia et al., 2003, PMID 12842853), and can be cyclized. As reported by Tzotzos et al., 2013, PMID 23313096, the biological activity of TIP peptides such as AP301 or solnatide (cyclo-CGQRETPEGAEAKPWYC; CGQRETPEGAEAKPWYC is SEQ ID NO:1) includes activation of the amiloride-sensitive epithelial sodium channel (ENaC).

[0013] Although unrelated to COVID-19, TIP peptides are known for use in the treatment of edema, in particular pulmonary edema, for example from European patents EP 1 247 531 B1 and EP 1 264 599 B1. Such peptides are also known for use in the treatment and prevention of vascular complications in diabetic patients, such as micro- and macroangiopathy, myocardial infarction, microvascular cardiac hyperpermeability, stroke, neuropathy, retinopathy, nephropathy or diabetic foot disease (EP 2 582 385 B1). Furthermore, such peptides are known for the prevention of edema by reducing hyperpermeability caused by damage to the endothelial and / or epithelial layers (EP 2 403 519 B1, also published as WO 2010 / 099556 A1). Furthermore, such peptides are known for use in the treatment and prevention of pulmonary type of mountain sickness (WO 2014 / 001177 A1). Such peptides are also known for use in the treatment or prevention of influenza when administered together with inhibitors of viral neuraminidase (WO 2012 / 065201 A1).Finally, WO 2015 / 140125 A2 relates to dry powder formulations of TIP peptides.

[0014] The peptides for use in the present invention are particularly suitable for patients before, after or during oxygen therapy or ventilation.Thus, in a preferred embodiment, the patient has been, is undergoing or is at risk of undergoing oxygen therapy (e.g., by mask or nasal prongs).Thus, in another preferred embodiment, the patient has been, is ventilated or is at risk of being ventilated, such as by non-invasive ventilation, preferably non-invasive positive pressure ventilation, or mechanical ventilation.

[0015] In a particularly preferred embodiment, the peptide is for use in patients who are in a hospital, preferably in an ICU, or who are at risk of being admitted to a hospital, preferably in an ICU, for the management of COVID-19.

[0016] To further enhance its beneficial effects in the lungs, the peptide is preferably administered to the patient by inhalation, preferably by oral inhalation or by intratracheal inhalation.

[0017] Peptides can be administered (in pharmaceutical compositions) via dry powder inhalers. Examples of such powder inhalers that can be used in the present invention are described in US Patent Nos. 4,995,385 and 4,069,819; existing products are SPINHALER®, ROTAHALER®, FLOWCAPS®, INHALATOR®, DISKHALER® and AEROLIZER®. Particularly preferred dry powder formulations of peptides are disclosed in WO 2015 / 140125 A2.

[0018] Alternatively, the peptide can be administered (in a pharmaceutical composition) via a nebulizer, typically continuously as long as the nebulizer is switched on or actuated by breathing. Examples of such nebulizers include existing products such as Aeroneb® and Pari®. Document US 9,364,618 B2 also discloses, for example, a nebulizer.

[0019] Finally, the peptide (in a pharmaceutical composition) can be administered via a metered dose inhaler. A metered dose inhaler is a device that aerosolizes (i.e. produces a relatively short burst of aerosol at a defined dose) a predetermined dose of a pharmaceutical composition, usually for self-administration by the patient. Metered dose inhalers are disclosed, for example, in US 6,260,549 B1.

[0020] Of course, the peptides can also be administered in other ways, such as, for example, intravenously.

[0021] According to particular preferences, the peptide is administered to the patient in a daily dose of 10 mg to 500 mg, preferably 50 mg to 400 mg, more preferably 75 mg to 350 mg, even more preferably 100 mg to 300 mg, even more preferably 125 mg to 175 mg, in particular 150 mg to 250 mg or even more preferably 175 mg to 225 mg.

[0022] To further enhance efficacy, it is preferred that the peptide is administered to the patient for at least 2 days, preferably at least 3 days, even more preferably at least 4 days, even more preferably at least 5 days, especially at least 6 days, or even more preferably at least 7 days.

[0023] Peptide can be administered with other drugs or alone.In a preferred embodiment, patient is further treated with, is receiving, or will be receiving at least one compound selected from the group consisting of: antiviral drugs such as remdesivir, favipiravir, lopinavir, ritonavir, ribavirin, taribavirin, umefenovir, amantadine, camostat and TMC-310911; chloroquine such as hydroxychloroquine and chloroquine; anti-interleukin-6 receptor antibody such as sarilumab, tocilizumab; interferon beta and angiotensin-converting enzyme 2.

[0024] The peptides disclosed herein are also suitable for the prophylaxis of patients at high risk of SARS-CoV-2 infection, particularly healthcare workers treating COVID-19 patients. Thus, in a preferred embodiment of the invention, the patient is at risk of developing COVID-19, preferably the patient is a healthcare worker, and / or the patient has been in close contact, is in close contact, or may be in close contact with another individual infected with SARS-CoV-2. In particular, for such patients, administration of the peptides by dry powder inhaler or metered dose inhaler is particularly suitable. As used herein, "close contact" is defined as contact within about 2 meters for a minimum of 10 minutes.

[0025] In a further preferred embodiment, the peptide of the invention is for reducing the risk of a patient progressing to COVID-19 with a severity score of 5 or 6 according to the WHO scoring scheme (see Table 1 above), preferably where the patient has COVID-19 with a severity score of 4 according to the WHO scoring scheme, or for reducing the risk of a patient progressing to COVID-19 with a severity score of 7 or 8 according to the WHO scoring scheme, preferably where the patient has COVID-19 with a severity score of 6 according to the WHO scoring scheme.

[0026] In yet another preferred embodiment, the peptide of the invention is for reducing a patient's COVID-19 severity score according to the WHO scoring system (see Table 1 above), in particular from 6 or 7 to 4 or 5.

[0027] The Sequential (or Sepsis) Organ Failure Assessment score (SOFA score) can be used to track the patient's condition during their ICU stay and to determine the extent or failure rate of the patient's organ function. The score is based on six different scores for the respiratory, cardiovascular, hepatic, coagulation, renal and nervous systems (see Vincent, JL., et al. "The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction / failure." (1996):707-710., PMID 8844239). The lower the SOFA score, the fewer the number of life-threatening organ failures and the higher the patient's survival rate. The present invention has been found to be very suitable for lowering the SOFA score of COVID-19 patients (see Example 2). It is therefore preferred that the (treated) patient has a SOFA score of at least 8, preferably at least 9, more preferably at least 10, even more preferably at least 11, in particular at least 12. In a further preferred embodiment, the present invention is for increasing the patient's organ function or for decreasing the patient's SOFA score.

[0028] Lung compliance is a measure of the lung's ability to stretch (the extensibility of elastic tissue). A lower compliance indicates a stiffer lung, whereas a higher compliance indicates a healthier and more elastic lung. The present invention has been found to be very suitable for increasing lung compliance in COVID-19 patients (see Example 2). Thus, preferably, the dynamic lung compliance (also called Cdyn, measured in mL / cm H2O) of the (treated) patient is at most 50, preferably at most 45, more preferably at most 40, even more preferably at most 35. In a further preferred embodiment, the present invention is for increasing the lung compliance of a patient, in particular the dynamic lung compliance.

[0029] Normal human body temperature (normothermia, euthermia) is the typical temperature range found in humans. The normal human body temperature range is usually taken to be 36.5-37.5°C. Body temperature is a general measure of the patient's general condition. The present invention has been found to be very suitable for lowering the body temperature of COVID-19 patients (see Example 2). It is therefore preferred that the body temperature of the patient (subject of treatment) is 37.5°C or higher, in particular 38°C or higher. In a further preferred embodiment, the present invention is for lowering the body temperature of a patient.

[0030] It has also been found that the present invention is particularly suitable for reducing the risk of death (see Example 2). Therefore, in a further preferred embodiment, the present invention is intended to reduce the risk of death of a patient.

[0031] Peptides for use according to the invention are known per se, for example from the following patent documents: EP 1 264 599 B1, US 2007 / 299003 A1, WO 94 / 18325 A1, WO 00 / 09149 A1, WO 2006 / 013183 A1 and WO 2008 / 148545 A1.

[0032] Preferably, the peptides used according to the invention contain the amino acid hexamer TPEGAE (SEQ ID NO:2), which is a potential carbohydrate-binding motif (Marquardt et al., 2007, PMID 17918767) and may enhance biological activity.

[0033] In a preferred embodiment of the invention, peptides for use according to the invention are cyclic (or cyclized) in order to retain as much of the original TNF-α conformation as possible (Elia et al., 2003, PMID 12842853), which may lead to higher biological activity. This is an optional feature, since according to Marquard et al., 2007, PMID 17918767, carbohydrate linkages important for biological activity may not require peptide cyclization.

[0034] In a preferred embodiment, the peptide of the invention comprises the amino acid hexamer TPEGAE (SEQ ID NO: 2). Preferably, the peptide is cyclic and comprises a sequence of consecutive amino acids selected from the group consisting of: - QRETPEGAEAKPWY (SEQ ID NO:3) - PKDTPEGAELKPWY (SEQ ID NO:4) - CGQRETPEGAEAKPWYC (SEQ ID NO:1) - CGPKDTPEGAELKPWYC (SEQ ID NO:5) and - a fragment of at least 7 amino acids comprising the hexamer TPEGAE (SEQ ID NO: 2). Such a peptide or a fragment thereof may have a biological activity, for example as shown in WO 2014 / 001177.

[0035] In another preferred embodiment of the invention, the peptide is administered as the sole active agent.

[0036] In a particularly preferred embodiment, the peptide according to the invention is the peptide AP301 or solnatide (CGQRETPEGAEAKPWYC, SEQ ID NO:1), in which solnatide is cyclized via the C residues, preferably by a disulfide bond between the C residues.

[0037] In a preferred embodiment, the peptides for use in the present invention may be formulated into a pharmaceutical composition. The expression "pharmaceutical composition" refers to any composition comprising at least one active agent (i.e., peptide), and preferably one or more excipients, which are pharma- ceutically acceptable for administration (particularly by inhalation) to an individual, particularly a mammal, especially a human. Suitable excipients are known to those skilled in the art and include, for example, water (particularly water for injection), saline, Ringer's solution, dextrose solution, buffers, Hank's solution, vesicle-forming compounds (e.g., lipids), fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives such as benzalkonium chloride. The pharmaceutical compositions according to the invention are liquid or can be readily dissolved in liquids such as sterile water, deionized or distilled water, or sterile isotonic phosphate-buffered saline (PBS). Preferably, 1000 μg (dry weight) of such a composition comprises or consists of 0.1-990 μg, preferably 1-900 μg, more preferably 10-200 μg of peptide, and optionally 1-500 μg, preferably 1-100 μg, more preferably 5-15 μg of (buffer) salt (preferably to produce an isotonic buffer in the final volume), and optionally 0.1-999.9 μg, preferably 100-999.9 μg, more preferably 200-999 μg of other excipients. Preferably, 100 mg of such a dry composition is dissolved in sterile deionized / distilled water or sterile isotonic phosphate buffered saline (PBS) to obtain a final volume of 0.1-100 ml, preferably 0.5-20 ml, more preferably 1-10 ml. However, the dosage and method of administration will usually vary depending on the individual to be treated. In general, the peptides may be administered at a dose between 1 μg / kg and 10 mg / kg, more preferably between 10 μg / kg and 5 mg / kg, and most preferably between 0.1 and 2 mg / kg.

[0038] As used herein, a peptide according to the present invention that "has no TNF receptor binding activity" or "does not exhibit TNF receptor binding activity" is intended to mean a peptide that has / does not exhibit sufficient TNF receptor binding activity to cause TNF-specific inflammatory activity detrimental to successful treatment of a patient.

[0039] In particular, "TNF-specific inflammatory activity detrimental to successful patient treatment" may mean: in an ex vivo safety pharmacology study of the peptide in human whole blood samples, carried out to assess whether addition of the peptide results in the release of the pro-inflammatory marker interleukin-6 (IL-6) from fresh human whole blood, addition of the peptide to a concentration of 10 mg / ml in the blood sample results in the release of less than 0.5 pg / ml of IL-6 (see EP 2 582 385 A1, Example 2).

[0040] As used herein, the term "effective amount" (of a peptide) refers to an amount that is effective enough to cause an intended therapeutic or preventive effect, for example, to prevent further deterioration of a disease or condition, to treat such deterioration, or to promote healing, or to cure a disease or condition. Usually, an effective amount is prescribed for an average patient. However, the actual effective amount (or dose) may be prescribed depending on one or more selected from the group including: the age, weight, general health condition of the patient; the severity and progression of the disease or condition.

[0041] The present invention is further illustrated in the following examples and figures, without however being limited thereto. [Brief description of the drawings]

[0042] [Figure 1] Figure 1 shows the mean Sequential Organ Failure Assessment (SOFA) scores of COVID-19 patients treated with solunatide twice daily for 7 days. [Diagram 2]Figure 2 shows the mean dynamic lung compliance (mL / cm H2O) in COVID-19 patients treated with solnatide twice daily for 7 days. [Diagram 3] Figure 3 shows the mean body temperatures (°C) of COVID-19 patients treated with solnatide twice daily for 7 days. Example 1

[0043] Clinical Trials in COVID-19 Patients On April 11, 2020, the "COV-2-SOLNATIDE-20" clinical trial of solnatide was initiated in mechanically ventilated COVID-19 patients (European Union medicines regulator's clinical trials database - EudraCT number 2020-001244-26).

[0044] This is a Phase II, randomized, placebo-controlled, double-blind pilot study. Each patient will have a maximum treatment period of 7 days, with a maximum study period of 28 days. Approximately 40 patients will be randomized in a 1:1 ratio to receive either placebo or 200 mg of solnatide per day.

[0045] Administration is by intratracheal inhalation with an Aeroneb® nebulizer. Solnatide is formulated as a powder for reconstitution and reconstituted with water for injection.

[0046] Solatide group: 100 mg of solatide was reconstituted with water for injection and administered into the lungs 14 times every 12 hours in a double-blind study.Placebo group: 14 doses of placebo (water for injection) were administered into the lungs every 12 hours.

[0047] Endpoints included: ventilator-free days within 28 days (ventilator-free days, VFD), time to extubation by day 28, all-cause mortality by day 28, score change according to the WHO scoring system in Table 1 (assessed 14 and 28 days after randomization), number of hospital days by day 28, and number of ICU days by day 28.

[0048] It is highly plausible that the peptides of the invention provide improvement with respect to at least one of these endpoints. Example 2

[0049] Community patients with serious health conditions were admitted to local hospitals for testing. In some of these patients, COVID-19 was confirmed by positive testing for SARS-CoV-2 by nasopharyngeal swabs and real-time RT-PCR.

[0050] As their condition worsened, severe COVID-19 patients were admitted to the hospital's ICU. Half of the patients were treated with orally inhaled solnatide twice daily for seven days, in addition to standard critical care and life support.

[0051] In parallel, a separate cohort of critically ill COVID-19 patients with comparable life-threatening conditions were treated in the hospital's ICU: these patients were treated with placebo alone, in addition to standard critical care and life support.

[0052] During the 7-day observation period, patient-centered clinical parameters reflecting the severity of COVID-19 were recorded.

[0053] During the 7-day observation period, patient-centered clinical parameters reflecting the severity of COVID-19 were recorded.

[0054] The SOFA score was used to track patients' condition during their stay in the intensive care unit (ICU) and to determine the degree of organ function or rate of failure of patients.

[0055] Figure 1 shows the mean SOFA scores of COVID-19 patients who received solnatide twice daily for 7 days. The mean SOFA score decreased from 12 to 8 during the treatment period.

[0056] In contrast, the SOFA scores of severe COVID-19 patients not receiving solnatide treatment did not decrease over the same period.

[0057] Figure 2 shows the mean dynamic lung compliance in COVID-19 patients treated with solnatide twice daily for 7 days. Mean dynamic lung compliance increased from approximately 35 mL / cm H2O to 50 mL / cm H2O during the treatment period.

[0058] In contrast, dynamic lung compliance in critically ill COVID-19 patients not receiving solnatide treatment remained below 40 mL / cm H2O over the same period.

[0059] Figure 3 shows the mean body temperatures of COVID-19 patients treated with solnatide twice daily for 7 days. The mean body temperatures were elevated at the start of treatment but decreased over the 7-day treatment period.

[0060] In contrast, temperatures in severe COVID-19 patients not receiving solnatide treatment were consistently above 38°C.

[0061] It is known from the scientific literature that the mortality rate of severe COVID-19 patients reaches 50% in those treated in ICUs (Tzotzos et al. Incidence of ARDS and outcomes in hospitalized patients with COVID-19. Critical Care (2020) 24:516; PMID 32825837). In the current observations, no severe COVID-19 patients treated with solnatide died within 28 days after the onset of COVID-19 symptoms. In contrast, in a comparison cohort composed of similarly severe COVID-19 patients, three patients died within 28 days.

Claims

1. 1. A pharmaceutical composition for the prevention or treatment of COVID-19 in a patient having or at risk of developing COVID-19, comprising a peptide that does not exhibit TNF receptor binding activity and that consists of the amino acid sequence CGQRETPEGAEAKPWYC, and that is cyclized.

2. 10. The pharmaceutical composition of claim 1, wherein the patient has been receiving, is receiving, or is at risk of receiving oxygen therapy.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the patient has been, is being ventilated or is at risk of being ventilated by non-invasive ventilation, including non-invasive positive pressure ventilation, or mechanical ventilation.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the patient is in a hospital, including an ICU, or at risk of being admitted to a hospital, including an ICU, for the management of COVID-19.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the peptide is administered to the patient by inhalation, including oral inhalation, or by intratracheal inhalation.

6. The peptide is administered to the patient at a daily dose of 10 mg to 500 mg, 50 mg to 400 mg, 75 mg to 350 mg, 100 mg to 300 mg, 125 mg to 175 mg, 150 mg to 250 mg, or 175 mg to 225 mg; and / or The pharmaceutical composition of any one of claims 1 to 5, wherein the peptide is administered to the patient for at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days or at least 7 days.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the patient has further undergone, is undergoing, or is about to undergo treatment with at least one compound selected from the group consisting of antiviral drugs; chloroquine; anti-interleukin-6 receptor antibodies; interferon beta and angiotensin-converting enzyme 2.

8. 8. The pharmaceutical composition of claim 7, wherein the antiviral drug is selected from the group consisting of remdesivir, favipiravir, lopinavir, ritonavir, ribavirin, taribavirin, umefenovir, amantadine, camostat and TMC-310911; the chloroquine is selected from the group consisting of hydroxychloroquine and chloroquine; and the anti-interleukin-6 receptor antibody is selected from the group consisting of sarilumab and tocilizumab.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the patient is a healthcare worker at risk of developing COVID-19 and / or the patient has been in close contact, is in close contact or may be in close contact with another individual infected with SARS-CoV-2.

10. 9. The pharmaceutical composition according to any one of claims 1 to 8, for reducing the risk of a patient with COVID-19 with a severity score of 4 according to the WHO scoring scheme progressing to COVID-19 with a severity score of 5 or 6, or for reducing the risk of a patient with COVID-19 with a severity score of 6 according to the WHO scoring scheme progressing to COVID-19 with a severity score of 7 or 8.

11. The pharmaceutical composition according to any one of claims 1 to 8, for reducing a patient's COVID-19 severity score from 6 or 7 to 4 or 5 according to the WHO scoring system.

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the peptide is cyclized via the C residues or by a disulfide bond between the C residues.

13. 13. The pharmaceutical composition of any one of claims 1 to 12, wherein the patient has a Sequential Organ Failure Assessment (SOFA) score of at least 8, at least 9, at least 10, at least 11, or at least 12.

14. The pharmaceutical composition according to any one of claims 1 to 13 for increasing organ function or decreasing the SOFA score of a patient.

15. Patients were asked to choose between a maximum of 50, a maximum of 45, a maximum of 40, or a maximum of 35 mL / cm H 2 15. The pharmaceutical composition according to any one of claims 1 to 14, having a pulmonary compliance of O.

16. A pharmaceutical composition according to any one of claims 1 to 15 for increasing the pulmonary compliance of a patient.

17. 17. The pharmaceutical composition of claim 16, wherein the lung compliance is dynamic lung compliance.

18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the patient has a body temperature of 37.5°C or higher, or 38°C or higher.

19. A pharmaceutical composition according to any one of claims 1 to 18 for reducing the body temperature of a patient.

20. The pharmaceutical composition according to any one of claims 1 to 19 for reducing the risk of death in a patient.

Citation Information

Patent Citations

  • Compositions containing pulmonary surfactant and tnf-derived peptides

    JP2008509107A

  • Prevention and treatment methods for increased permeability

    JP2012519188A

  • Composition comprising peptides and viral neuraminidase inhibitors

    JP2014501718A

  • dry powder peptide medicine

    JP2017510633A